NEW YORK (Reuters Health) – The glucagon-like peptide 1 analog taspoglutide administered subcutaneously once weekly improves glycemic control and reduces body weight in drug-naive patients with type 2…
NEW YORK (Reuters Health) – If lifestyle changes are not enough to control type 2 diabetes, metformin should be the first oral agent added to treatment, according to…
NEW YORK (Reuters Health) – A French team concludes that routine neonatal screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21-OHD) should be discontinued for preterm infants,…
NEW YORK (Reuters Health) – Patients with type 2 diabetes who don’t have retinopathy at baseline have a relatively low risk of developing eye complications during 5 to…
NEW YORK (Reuters Health) – Fenofibrate is safe to use in patients with type 2 diabetes and moderate renal impairment, researchers conclude in a report online December 30…
NEW YORK (Reuters Health) – Based on the 2010 American Diabetes Association’s definition of prediabetes, the condition is present in over a third of psychiatric inpatients treated with…
NEW YORK (Reuters Health) – Parental fear of hypoglycemia probably blunts the potential benefits of continuous glucose monitoring in children with type 1 diabetes, researchers conclude in a…
NEW YORK (Reuters Health) – Patients with focal forms of congenital hyperinsulinism are likely to be cured of hypoglycemia after partial pancreatectomy, clinicians from France report in the…
NEW YORK (Reuters Health) – Three years of weekly treatment with a sustained-release formulation of growth hormone is as safe and effective as standard daily growth hormone (GH)…
NEW YORK (Reuters Health) – Cirrhosis and hepatitis are associated with the occurrence of hepatocellular carcinoma (HCC) in patients with diabetes, and hepatitis C is of particular importance,…